Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-163,447
Closed -$347K 1840
2024
Q3
$347K Hold
163,447
﹤0.01% 761
2024
Q2
$306K Hold
163,447
﹤0.01% 767
2024
Q1
$433K Hold
163,447
﹤0.01% 738
2023
Q4
$503K Hold
163,447
﹤0.01% 744
2023
Q3
$258K Hold
163,447
﹤0.01% 799
2023
Q2
$322K Hold
163,447
﹤0.01% 816
2023
Q1
$315K Hold
163,447
﹤0.01% 848
2022
Q4
$343K Hold
163,447
﹤0.01% 824
2022
Q3
$374K Hold
163,447
﹤0.01% 813
2022
Q2
$463K Hold
163,447
﹤0.01% 775
2022
Q1
$742K Hold
163,447
﹤0.01% 733
2021
Q4
$1.33M Hold
163,447
﹤0.01% 670
2021
Q3
$2.06M Buy
163,447
+36,862
+29% +$511K 0.01% 658
2021
Q2
$1.96M Buy
126,585
+45,667
+56% +$768K 0.01% 670
2021
Q1
$1.64M Buy
80,918
+3,187
+4% +$78.8K 0.01% 684
2020
Q4
$2.1M Buy
77,731
+29,649
+62% +$665K 0.01% 633
2020
Q3
$890K Buy
48,082
+14,569
+43% +$259K 0.01% 728
2020
Q2
$597K Buy
33,513
+14,892
+80% +$227K ﹤0.01% 788
2020
Q1
$171K Hold
18,621
﹤0.01% 1061
2019
Q4
$319K Hold
18,621
﹤0.01% 1216
2019
Q3
$194K Hold
18,621
﹤0.01% 1259
2019
Q2
$290K Hold
18,621
﹤0.01% 1175
2019
Q1
$342K Buy
18,621
+4,355
+31% +$77.2K ﹤0.01% 1164
2018
Q4
$238K Buy
14,266
+2,661
+23% +$61.7K ﹤0.01% 1099
2018
Q3
$327K Hold
11,605
﹤0.01% 1213
2018
Q2
$328K Hold
11,605
﹤0.01% 1082
2018
Q1
$366K Sell
11,605
-1,244
-10% -$39.3K ﹤0.01% 1022
2017
Q4
$375K Hold
12,849
﹤0.01% 1025
2017
Q3
$366K Buy
+12,849
New +$332K ﹤0.01% 1025

Other funds holding CLLS

KBC Group's CLLS Position: Q4 2024 in Review

KBC Group sold out of Cellectis (CLLS) in Q4 2024, closing a stake of 163,447 shares — an estimated $347K sold.

KBC Group first reported a position in CLLS in Q3 2017 and held it in 29 quarters. The position peaked at $2.1M in Q4 2020. 29 funds tracked by Wall St. Rank hold CLLS as of Q4 2024.

  • KBC Group reported no remaining Cellectis position as of Q4 2024 after selling out during the quarter.
  • KBC Group sold 163,447 Cellectis shares in Q4 2024, an estimated $347K.
  • KBC Group first reported a position in Cellectis in Q3 2017 and held it in 29 quarters.
  • KBC Group's Cellectis position peaked at $2.1M in Q4 2020.
  • 29 funds tracked by Wall St. Rank held Cellectis as of Q4 2024.

Based on KBC Group's 13F filing for Q4 2024, filed 22 Jan 2025.